Most phosphaturic substance in human body
FGF-23 (Fibroblast Growth Factor 23) is the most potent phosphaturic substance in the human body. It is produced primarily by osteocytes and osteoblasts in bone, and it acts on the kidneys to reduce phosphate reabsorption by downregulating sodium-phosphate cotransporters (NaPi-IIa and NaPi-IIc) in the proximal tubule. It also suppresses 1-alpha-hydroxylase, reducing active vitamin D production.
Searching sources...
Reading File
Searching the Web
most potent phosphaturic substance human body FGF-23 PTH
Finding Sources
Reading File
Reading File
FGF-23 - The Most Phosphaturic Substance in the Human Body
FGF-23 (Fibroblast Growth Factor 23) is the most potent phosphaturic substance in the human body. It is also called a "phosphatonin" - a term coined by Econs and Drezner for factors that lower blood phosphorus levels.
Key Facts
| Feature | Detail |
|---|---|
| Structure | 251-amino acid peptide, 26 kDa; gene on chromosome 12p13.3 |
| Source | Osteocytes and osteoblasts in bone (primarily) |
| Co-receptor required | α-Klotho (essential for FGF-23 signaling) |
| Receptor | FGFR1c (primarily), FGFR4 (lesser degree) |
Mechanism of Action
FGF-23 acts on the kidney via Klotho-FGF receptor (FGFR1c) complexes and produces two major effects:
-
Phosphaturic effect: Causes endocytosis and downregulation of NaPi-IIa (NPT2A) and NaPi-IIc (NPT2C) sodium-phosphate cotransporters in the proximal tubule → decreased phosphate reabsorption → phosphaturia
-
Anti-vitamin D effect: Suppresses renal 1α-hydroxylase (CYP27B1) and upregulates 24-hydroxylase → decreased 1,25(OH)₂D (calcitriol) production → less GI phosphate absorption
This two-pronged action makes FGF-23 the dominant regulator of phosphate homeostasis.
Comparison with PTH
While PTH is also phosphaturic (it downregulates NPT2A/2C via NHERF-1), FGF-23 and PTH differ importantly:
| FGF-23 | PTH | |
|---|---|---|
| Phosphaturia | Yes | Yes |
| Effect on 1,25(OH)₂D | Decreases | Increases |
| Net phosphate balance | Lower | Lower |
| Potency as phosphatonin | Primary (most potent) | Secondary |
FGF-23 is considered more potent because it is the master regulator of phosphate homeostasis - it acts on both renal reabsorption AND intestinal absorption (via vitamin D suppression). PTH's phosphaturic action can even develop partial resistance in the absence of FGF-23 signaling.
Regulation of FGF-23 Secretion
FGF-23 is stimulated by:
- High serum phosphate
- 1,25(OH)₂D (calcitriol)
- PTH
- Iron deficiency (via HIF-1α)
- Cleaved/soluble Klotho
FGF-23 is suppressed by:
- Dietary phosphate restriction
- Calcium deficiency
- DMP-1 (dentin matrix protein-1) and PHEX - local bone-derived negative regulators
Clinical Relevance
Excess FGF-23 causes phosphate-wasting disorders:
- X-linked hypophosphatemia (XLH) - PHEX mutations lead to excess FGF-23
- Autosomal dominant hypophosphatemic rickets (ADHR) - gain-of-function FGF-23 mutations resist cleavage
- Tumor-induced osteomalacia (TIO) - phosphaturic mesenchymal tumors secrete FGF-23
- CKD-MBD - elevated FGF-23 rises earliest in CKD (even before serum phosphate or PTH rise)
Deficient FGF-23 causes hyperphosphatemia (as seen in advanced CKD when FGF-23 response is overwhelmed).
Sources: Tietz Textbook of Laboratory Medicine, 7th Ed. | Goodman & Gilman's Pharmacological Basis of Therapeutics | FGF23 and Phosphate Wasting Disorders (Nature/Bone Research)
This is a shared conversation. Sign in to Orris to start your own chat.